Correlation of paxillin copy number (FISH) with EGFR (exon 19/21) and KRAS (codons12/13) mutation
| Tumour histology | Paxillin FISH | EGFR exon 19 | EGFR exon 21 | KRAS codons 12/13 |
| Adenocarcinoma (1.5 cm), solid and acinar types, with focal signet ring features | Amplification | WT | WT | WT |
| Adenocarcinoma with BAC pattern* | Amplification | WT | WT | Mutation |
| Adenocarcinoma (1.6 cm) | Diploid | WT | WT | WT |
| Adenocarcinoma (0.5 cm), acinar type | Diploid | WT | WT | WT |
| Large cell carcinoma (1.7 cm) | Diploid | WT | WT | WT |
| Squamous cell carcinoma (3.0 cm) | Diploid | WT | WT | NA |
| Focal squamous metaplasia with dysplasia | Diploid | WT | WT | WT |
| High-grade squamous cell carcinoma (3.7 cm) | Diploid | WT | WT | WT |
| Adenosquamous carcinoma (1.2 cm) | Diploid | WT | WT | WT |
| Adenocarinoma (3.5 cm) with sarcomatoid changes | Diploid | WT | WT | NA |
| Adenosquamous carcinoma (1.2 cm) | Diploid | WT | WT | WT |
↵* Paxillin overexpression confirmed with immunohistochemistry.
BAC, bronchioloalveolar carcinoma; FISH, fluorescence in situ hybridisation; NA, KRAS PCR amplification failed; WT, wild-type.